FY2024 EPS Estimates for Bruker Boosted by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Bruker in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $2.39 per share for the year, up from their prior estimate of $2.38. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Leerink Partnrs also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $2.74 EPS, FY2026 earnings at $3.16 EPS and FY2027 earnings at $3.65 EPS.

Several other research analysts have also recently commented on BRKR. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. TD Cowen cut their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. Bank of America upped their target price on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Finally, UBS Group started coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective for the company. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $74.45.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $58.19 on Wednesday. The business has a fifty day simple moving average of $58.04 and a 200-day simple moving average of $61.58. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The company has a market cap of $8.82 billion, a P/E ratio of 27.98, a P/E/G ratio of 3.51 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.74 earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. True Wealth Design LLC boosted its stake in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 510 shares during the last quarter. Eagle Bay Advisors LLC increased its holdings in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after buying an additional 674 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker in the 2nd quarter valued at $52,000. Finally, GAMMA Investing LLC boosted its position in Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after buying an additional 388 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. This represents a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 28.30% of the stock is owned by insiders.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker’s dividend payout ratio is presently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.